[go: up one dir, main page]

BRPI0910557A2 - composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. - Google Patents

composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.

Info

Publication number
BRPI0910557A2
BRPI0910557A2 BRPI0910557A BRPI0910557A BRPI0910557A2 BR PI0910557 A2 BRPI0910557 A2 BR PI0910557A2 BR PI0910557 A BRPI0910557 A BR PI0910557A BR PI0910557 A BRPI0910557 A BR PI0910557A BR PI0910557 A2 BRPI0910557 A2 BR PI0910557A2
Authority
BR
Brazil
Prior art keywords
paclitaxel
preparation
pharmaceutical compositions
conjugates
related methods
Prior art date
Application number
BRPI0910557A
Other languages
English (en)
Inventor
Anthony Regina
Catherine Gagnon
Christian Che
Jean-Paul Castaigne
Michel Demeule
Reinhard Gabathuler
Richard Beliveau
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of BRPI0910557A2 publication Critical patent/BRPI0910557A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0910557A 2008-04-18 2009-04-20 composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso. BRPI0910557A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12467708P 2008-04-18 2008-04-18
PCT/CA2009/000542 WO2009127072A1 (en) 2008-04-18 2009-04-20 Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use

Publications (1)

Publication Number Publication Date
BRPI0910557A2 true BRPI0910557A2 (pt) 2015-09-29

Family

ID=41198750

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910557A BRPI0910557A2 (pt) 2008-04-18 2009-04-20 composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.

Country Status (16)

Country Link
US (1) US8710013B2 (pt)
EP (1) EP2279008B1 (pt)
JP (2) JP5860698B2 (pt)
CN (1) CN102026667B (pt)
AU (1) AU2009238187B2 (pt)
BR (1) BRPI0910557A2 (pt)
CA (1) CA2721019C (pt)
DK (1) DK2279008T3 (pt)
ES (1) ES2721148T3 (pt)
MX (1) MX355683B (pt)
PL (1) PL2279008T3 (pt)
PT (1) PT2279008T (pt)
RU (1) RU2518240C2 (pt)
TR (1) TR201905480T4 (pt)
WO (1) WO2009127072A1 (pt)
ZA (1) ZA201007170B (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060403A2 (en) 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1859041B2 (en) 2005-02-18 2014-11-19 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
AU2009304560A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of GLP-1 agonists and uses thereof
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
WO2010069074A1 (en) 2008-12-17 2010-06-24 Universite Du Quebec A Montreal Membrane type-1 matrix metalloprotein inhibitors and uses thereof
AU2010239069B2 (en) 2009-04-20 2015-05-14 Angiochem Inc Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
AU2011248449B2 (en) 2010-05-03 2016-09-15 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
WO2013043864A1 (en) * 2011-09-23 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions and methods related to endothelial targeting
WO2014026283A1 (en) 2012-08-14 2014-02-20 Angiochem Inc. Peptide-dendrimer conjugates and uses thereof
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
US10398785B2 (en) * 2015-03-16 2019-09-03 Meridian Lab Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
EP3307326B9 (en) * 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
AU2017259576B2 (en) * 2016-05-06 2020-09-17 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition
JP7421499B2 (ja) * 2018-05-15 2024-01-24 アメリカ合衆国 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
KR20210078505A (ko) * 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
CN110227086A (zh) * 2019-07-13 2019-09-13 高天荣 一种用人工种植红豆杉制备口服广普抗癌药的方法
CN114929213A (zh) 2020-04-13 2022-08-19 美国纳米食品药品公司 碱性化疗药瘤内注射剂组合物
CN111671759A (zh) * 2020-07-15 2020-09-18 五邑大学 一种协同抗胰腺癌干细胞的药物组合
CN113406015B (zh) * 2021-05-31 2023-01-13 内蒙古师范大学 一种近岸和内陆水域水体的透明度计算方法和系统
WO2024178236A1 (en) * 2023-02-22 2024-08-29 N1 Life, Inc. Taxol conjugate compounds and pharmaceutical compositions thereof

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US4904768A (en) 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US6495513B1 (en) 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2145517A1 (en) 1992-09-25 1994-04-14 Ignace Lasters Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex
EP0599303A3 (en) 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994019692A1 (en) 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
ZA963619B (en) 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
IL126115A (en) 1996-03-11 2007-03-08 Aerovance Inc Significantly purified protein with suppressive activity for sirin protease and its pharmaceutical preparations
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
EP0932390A1 (en) 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO1998039469A1 (en) 1997-03-04 1998-09-11 Bio-Technology General Corp. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
IL132941A0 (en) 1997-05-21 2001-03-19 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
WO2000050059A1 (en) 1999-02-24 2000-08-31 The Uab Research Foundation Taxane derivatives for targeted therapy of cancer
US6180607B1 (en) 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
ATE364592T1 (de) 1999-09-24 2007-07-15 Genentech Inc Tyrosinderivate
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
EP1337273A2 (en) 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
IL157993A0 (en) 2001-03-23 2004-03-28 Napro Biotherapeutics Inc Molecular conjugates for use in cancer treatment and methods for the preparation thereof
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
ATE445838T1 (de) 2001-07-25 2009-10-15 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
WO2003066859A2 (en) 2002-02-07 2003-08-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
KR100608558B1 (ko) 2002-03-29 2006-08-03 크레아젠 주식회사 세포질 잔류성 세포막 투과 펩타이드 및 이의 용도
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
JP2005537244A (ja) 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
EP2305813A3 (en) 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US7829694B2 (en) 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
WO2004060403A2 (en) * 2003-01-06 2004-07-22 Angiochem Inc. Aprotinin and anglos as carriers across the blood-brain barrier
US20040162284A1 (en) 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
WO2005046569A2 (en) 2003-04-08 2005-05-26 Biotempt B.V. Pharmaceutical compositions for the treatment of sars
HRP20150037T4 (hr) * 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
EP2660322A3 (en) 2003-04-17 2013-11-13 Alnylam Pharmaceuticals Inc. Modified iRNA agents
EP2281577B1 (en) * 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
AU2003286870A1 (en) 2003-06-05 2005-01-04 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
EP1638605B1 (en) 2003-06-20 2014-01-08 Raptor Pharmaceutical, Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP4806258B2 (ja) 2003-08-08 2011-11-02 株式会社ACTGen 脳移行活性を有するポリペプチド、およびその利用
EP1663278A4 (en) 2003-08-28 2009-07-29 Biorexis Pharmaceutical Corp EPO MIMETIC PEPTIDES AND FUSION PROTEINS
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20050058702A1 (en) 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
WO2006091231A2 (en) 2004-07-21 2006-08-31 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1771467A2 (en) 2004-07-26 2007-04-11 Asterion Limited Linkers
CA2580189C (en) 2004-09-29 2013-05-21 Children's Memorial Hospital Sirna-mediated gene silencing of alpha synuclein
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
US20090016959A1 (en) 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
EP1859041B2 (en) 2005-02-18 2014-11-19 Angiochem Inc. Aprotinin polypeptides for transporting a compound across the blood-brain barrier
BRPI0607809A2 (pt) * 2005-02-18 2009-06-13 Abraxis Bioscience Inc uso de uma composição compreendendo nanopartìculas, composição e kit
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
KR20080030564A (ko) 2005-05-12 2008-04-04 태피스트리 파마슈티컬스 인코퍼레이티드 표적 컨쥬게이트에 적합한 분자 구조물
WO2006138343A2 (en) 2005-06-14 2006-12-28 Raptor Pharmaceutical Inc. Compositions comprising receptor - associated protein (rap) variants specific for lrp2 and uses thereof
ES2744225T3 (es) 2005-07-15 2020-02-24 Angiochem Inc Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
EP1904642A4 (en) 2005-07-19 2008-11-26 Univ Illinois TRANSPORT AGENTS FOR CROSS-BREAKING BLOOD-BRAIN DISEASE AND INTRUSION IN BRAIN CANCER CELLS AND METHOD OF USE THEREOF
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
SI3311805T1 (sl) * 2005-08-31 2020-07-31 Abraxis Bioscience, Llc Sestave, ki zajemajo slabo vodotopne farmacevtske učinkovine in antimikrobna sredstva
WO2007035716A2 (en) 2005-09-16 2007-03-29 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
US8053569B2 (en) 2005-10-07 2011-11-08 Armagen Technologies, Inc. Nucleic acids encoding and methods of producing fusion proteins
US20070197460A1 (en) 2005-11-01 2007-08-23 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
EP2043696B1 (en) 2006-07-13 2015-02-25 Burnham Institute for Medical Research Methods and compositions for targeting gc1qr/p32
JP2010503710A (ja) 2006-09-18 2010-02-04 ラプトール ファーマシューティカル インコーポレイテッド 受容体関連タンパク質(rap)結合体の投与による肝障害の処置
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
BRPI0809234A2 (pt) 2007-03-21 2014-09-02 Raptor Pharmaceutical Inc Peptídeos de proteína associada a receptor (rap) cíclico
CA2688344C (en) * 2007-05-29 2019-09-03 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
JP2012528596A (ja) 2009-06-03 2012-11-15 ダイセルナ ファーマシューティカルズ, インコーポレイテッド ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法
EP3000481A3 (en) 2009-07-14 2016-05-11 Mayo Foundation for Medical Education and Research Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US9180105B2 (en) 2010-03-08 2015-11-10 Sloan-Kettering Institute For Cancer Research CDC7 kinase inhibitors and uses thereof
US9102697B2 (en) 2010-03-22 2015-08-11 President And Fellows Of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
US8986689B2 (en) 2010-04-14 2015-03-24 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
CA2815154A1 (en) 2010-08-06 2012-02-09 U3 Pharma Gmbh Use of her3 binding agents in prostate treatment
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
AU2011329638C1 (en) 2010-11-18 2017-04-27 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
US20130337051A1 (en) 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
DK2691443T3 (da) 2011-03-28 2021-05-03 Massachusetts Inst Technology Konjugerede lipomerer og anvendelser af disse
EP2696898A4 (en) 2011-04-07 2014-10-01 Univ Emory COMPOSITIONS WITH SACCHARIDE-BINDING PARTS AND PROCEDURE FOR TARGETED THERAPY
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013032591A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
NZ747501A (en) 2011-10-27 2020-05-29 Massachusetts Inst Technology Amino acid derivatives functionalized on the n-terminal capable of forming drug encapsulating microspheres
EP2776428A4 (en) 2011-11-11 2015-04-22 Intellikine Llc KINASEHEMMERPOLYMORPHE
WO2013078564A2 (en) 2011-12-01 2013-06-06 Angiochem Inc. Targeted lysosomal enzyme compounds
SMT202000676T1 (it) 2011-12-13 2021-01-05 Engeneic Molecular Delivery Pty Ltd Minicellule intatte di derivazione batterica per veicolazione di agenti terapeutici a tumori cerebrali
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
US20150037281A1 (en) 2012-03-02 2015-02-05 Icahn School Of Medicine At Mount Sinai Variants of prothymosin alpha and methods of using same

Also Published As

Publication number Publication date
CN102026667B (zh) 2014-06-25
HK1154795A1 (en) 2012-05-04
JP5860698B2 (ja) 2016-02-16
EP2279008A4 (en) 2013-09-04
EP2279008B1 (en) 2019-03-06
CA2721019A1 (en) 2009-10-22
CN102026667A (zh) 2011-04-20
AU2009238187A1 (en) 2009-10-22
JP2011516587A (ja) 2011-05-26
TR201905480T4 (tr) 2019-05-21
EP2279008A1 (en) 2011-02-02
CA2721019C (en) 2015-09-15
RU2010146718A (ru) 2012-05-27
ES2721148T3 (es) 2019-07-29
MX355683B (es) 2018-04-26
AU2009238187B2 (en) 2014-03-06
RU2518240C2 (ru) 2014-06-10
JP2015157825A (ja) 2015-09-03
PL2279008T3 (pl) 2020-03-31
WO2009127072A1 (en) 2009-10-22
MX2010011339A (es) 2010-12-21
US8710013B2 (en) 2014-04-29
US20110112036A1 (en) 2011-05-12
ZA201007170B (en) 2012-01-25
WO2009127072A8 (en) 2009-12-30
PT2279008T (pt) 2019-05-20
DK2279008T3 (en) 2019-04-29

Similar Documents

Publication Publication Date Title
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
CL2007002377A1 (es) Compuestos derivados de quinazolina; procedimiento de preparacion; composicion farmaceutica; y su uso como anticancerigeno.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI1008906A2 (pt) composto, composição farmacêutica, e, uso de um composto.
BRPI0913726A2 (pt) rapalogs, composições farmacêuticas, métodos de preparo e uso dos mesmos
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BRPI0915120A2 (pt) composto derivado de oxima, uso do referido composto e composição farmacêutica
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/337 (2006.01), A61K 9/00 (2006.01), A61K 9

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL